We cannot directly compare the phenotype of the whole-body PHD2 inhibition to our study as they were conducted under different environmental temperatures (RT vs TN) and disease models (NAFLD vs HFD). Here, EGLN1 is linked to metabolic dysfunction-associated steatotic liver disease.